Get started
Author

Lauren R. Flynn

ORCID: 0009-0007-3905-3782
Observed ORCID: 0009-0007-3905-3782
OpenAlex ID: A5065648202
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al. · Cancer Research · 14
PDF
Supplemental Table 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Data from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 2 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Table 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Table 2 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 8 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 7 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Table 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 9 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Table 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Supplemental Figure 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
2025 · Leanne G. Ahronian, Soumyadip Sahu, et al.
Works count: 17
Citation count: 14
H-index: 1
I10-index: 1
Year
Topic
Type